Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Irinotecan in Metastatic or Recurrent Malignant Melanoma
NCT07817901Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Nov 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in melanoma, sponsored by Yonsei University. Primary endpoint: Overall Response Rate up to 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pembrolizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07817901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817901.